Here's some key things from the Conference Call that I thought were pretty important, of course, IMHO:
Most folks are probably more interested in news from the "Complete Vaccine" & the NGIO Up-listing more than anything. But, there are other aspects of the Company that are moving along rather nicely such as the restart of the Alergen line & the start-up of the Remote Patient Monitoring. Both appear to be moving along very nicely and they both appear to be very close to Revenue producing which is pretty significant. Obviously, this Company has a lot more going for it than just the "Complete Vaccine" & NGIO Up-Listing. If anyone didn't listen in on the Conference Call last week, all one would have to do is read the most recent news related to GNBT to realize the progress in those other areas (or listen to the Conference Call audio on the company web page)!
As far as the "Complete Vaccine", one of the things that came out of the Conference Call had to do with Trial-1. Most folks look at the final product down the line, but if Trial-1 goes as the testing up to now indicates, the "Complete Vaccine" will be a "Homerun" at that point and there will be many many folks across the world interested in the "Complete Vaccine", long before Trial-2/3 are even completed per Joe. I believe Joe also implied we would then see some significant movement in the share price at that time! I believe Joe said Trial-2 & 3 may be combined but I didn't really understand that part of it nor have I gone back to listen to the audio again. Anyways, I believe Joe said Trial-1 will consist of 180 folks & take no more than 30 days. So, once IND approval happens, relatively soon, then there's huge potential for the share price to have significant movement upward when Trial-1 is completed! That is HUGE NEWS in itself IMHO!
As far as the NGIO Up-List, Joe said "it was going well, we believe shareholders will be happy very soon".
All-in-All, things are looking pretty darn good here in GNBT Land! Go GNBT & GLTA!
